Bernhard Gunther, CEO of Novaliq GmbH, delivers an update on the progress of his compay’s drug delivery pipeline. Novaliq develops innovative pharmaceutical formulations based on semifluorinated alkanes (SFAs). The company’s lead Rx product CyclASol is being tested as a treatment for moderate to severe dry eye. Novaliq also sells NovaTears, an over-the-counter treatment for Dry Eye.
Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in the field of ocular biopharmaceutics and medical devices.